Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Investments (2019 - 2022)

China SXT Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $1.6 million for Q3 2022.

  • For Q3 2022, Long-Term Investments changed 0.0% year-over-year to $1.6 million; the TTM value through Sep 2022 reached $1.6 million, changed 0.0%, while the annual FY2022 figure was $1.6 million, 0.0% changed from the prior year.
  • Long-Term Investments for Q3 2022 was $1.6 million at China SXT Pharmaceuticals, roughly flat from $1.6 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $3.5 million in Q3 2019 and troughed at $1.6 million in Q1 2020.
  • A 4-year average of $1.9 million and a median of $1.6 million in 2021 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: tumbled 54.03% in 2020 and later increased 0.86% in 2021.
  • Year by year, Long-Term Investments stood at $3.5 million in 2019, then plummeted by 54.03% to $1.6 million in 2020, then fell by 1.68% to $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022.
  • Business Quant data shows Long-Term Investments for SXTC at $1.6 million in Q3 2022, $1.6 million in Q1 2022, and $1.6 million in Q3 2021.